ARA-290 Peptide Therapy for Neuropathy: What It Is, Who It Helps, and How to Access It

Most people who land on this page have already been through the standard treatment circuit for neuropathy. Gabapentin, pregabalin, duloxetine, maybe a referral to pain management. The burning, the numbness, the shooting pain at night — it continues regardless. What they are looking for is something that addresses the underlying nerve damage, not something that turns down the volume on the signal while the damage progresses.

ARA-290 is a synthetic peptide derived from the tertiary structure of erythropoietin. It does not stimulate red blood cell production. What it does is activate a separate receptor system — the innate repair receptor — that sits on peripheral nerve fibers and drives tissue protection and nerve regeneration. The clinical evidence is strongest in small fiber neuropathy, and the research picture continues to build.

This is not something you order from a supplement site. ARA-290 requires a physician prescription through a compounding pharmacy, and before we discuss prescribing it, we review your case in full. The type of neuropathy you have, your current medications, your inflammatory markers, and what has already been tried all factor into whether ARA-290 makes sense for you and how to structure the protocol. This page explains the science, the evidence, and exactly how to start the process.

How ARA-290 Works: The Innate Repair Receptor

Erythropoietin (EPO) is widely known as the hormone that tells bone marrow to make more red blood cells. What most people do not know is that EPO also signals through a completely different receptor system throughout the body — one that has nothing to do with blood production. This second receptor, called the innate repair receptor (IRR), is assembled from the erythropoietin receptor and the common beta subunit of other cytokine receptors. It sits on nerve fibers, immune cells, and other tissues, and when activated, it drives repair rather than production.

ARA-290 was engineered specifically to activate the IRR without touching the erythropoietin receptor on red blood cell precursors. It was derived from the helix B surface of the EPO molecule — the region of the protein that interacts with the IRR. The result is a peptide with the tissue-protective and neuro-regenerative properties of EPO's signaling through the IRR, but without any effect on hematopoiesis. That separation is what makes it safe for long-term use in neuropathy without the cardiovascular risks associated with EPO itself.

When ARA-290 binds to the IRR on peripheral nerve fibers, it triggers two broad effects. First, it reduces local neuroinflammation by suppressing pro-inflammatory signaling in the nerve microenvironment. Second, it promotes nerve fiber survival and regrowth. In clinical studies, researchers measured this directly by looking at intraepidermal nerve fiber density — the number of small C-fiber endings in a skin biopsy — before and after treatment. In sarcoidosis patients with documented small fiber neuropathy, ARA-290 produced measurable increases in nerve fiber density alongside improvements in pain scores and autonomic function.

Who Is a Candidate for ARA-290 Therapy

The strongest candidates are patients with documented small fiber neuropathy who have not responded adequately to standard pharmacological management and who have identifiable inflammatory or metabolic drivers that are being addressed in parallel. A skin punch biopsy confirming reduced intraepidermal nerve fiber density is useful but not always required — the clinical picture and symptom pattern often tell the story clearly enough to move forward with a case review.

Sarcoidosis-associated neuropathy has the deepest evidence base for ARA-290 specifically. If you have a sarcoidosis diagnosis and peripheral neuropathy, this is a well-studied indication. Diabetic peripheral neuropathy is the second area with meaningful trial data, particularly for patients where blood sugar is now controlled but nerve damage persists or continues to progress despite that control.

Post-COVID small fiber neuropathy is an emerging area where the inflammatory mechanism and IRR pathway make ARA-290 a rational consideration. The evidence base here is earlier stage, but the pathophysiology supports it and we are seeing this in clinical practice. Chemotherapy-induced peripheral neuropathy and idiopathic small fiber neuropathy are also cases we evaluate, though the evidence is more limited and the decision depends heavily on what else is going on in the patient's overall picture.

Patients who are not good candidates include those with active untreated malignancy, those on certain immunosuppressive regimens where the interaction picture is unclear, and patients where the root driver of neuropathy has not been addressed — because no peptide will regenerate nerve fibers faster than ongoing inflammation or metabolic damage destroys them. We work through this during the case review.

What the Clinical Evidence Shows

The foundational work establishing ARA-290's mechanism was published by Brines and colleagues, who demonstrated that a peptide derived from the helix B surface of erythropoietin activates tissue-protective signaling through the innate repair receptor without erythropoietic activity. This separated the two functions of EPO pharmacologically for the first time and created a new class of tissue-protective peptides.

The most cited clinical application is in sarcoidosis-associated small fiber neuropathy. Dahan and colleagues published an open-label study showing that patients with sarcoidosis and documented small fiber neuropathy who received ARA-290 experienced long-term relief of neuropathic pain. A randomized double-blind pilot study in the same population followed, where ARA-290 again produced improvements in pain scores and corneal nerve fiber density — a surrogate measure for small fiber health measured non-invasively by corneal confocal microscopy.

In diabetic peripheral neuropathy, a randomized controlled trial examined ARA-290's effect on nerve fiber density and metabolic markers. The results showed not only neuropathic improvements but also effects on insulin sensitivity, which reflects the broader reach of IRR signaling into metabolic tissue. This cross-system effect is relevant for diabetic patients where neuropathy and metabolic dysfunction are intertwined.

The honest summary: the mechanism is well-established, the early-phase clinical results are positive, and the safety profile in trials has been favorable. ARA-290 is not FDA-approved and the long-term data set is still maturing. We use it within that framework — as a rational, evidence-informed option for patients who have a clear neuropathic picture and have not found adequate relief elsewhere.

How to Access ARA-290 Therapy at Mind Body Neurology

ARA-290 is available through compounding pharmacies with a physician prescription. We do not dispense it without first reviewing your case, because how we use it — the dose, the frequency, the duration, and what we monitor — depends entirely on your specific clinical situation. Here is how the process works.

For more on the clinical evaluation of small fiber neuropathy and the tests we use to characterize nerve damage, see our article on small fiber neuropathy diagnosis and treatment at Mind Body Neurology. If you are exploring the broader role of peptides in neurological repair, our peptide therapy overview covers additional agents. You can also browse targeted nerve-support supplements in our supplement dispensary.